| Uncovering growth-suppressive MicroRNAs in lung cancer X Liu, LF Sempere, F Galimberti, SJ Freemantle, C Black, KH Dragnev, ... Clinical Cancer Research 15 (4), 1177-1183, 2009 | 232 | 2009 |
| UBE1L causes lung cancer growth suppression by targeting cyclin D1 Q Feng, D Sekula, Y Guo, X Liu, CC Black, F Galimberti, SJ Shah, ... Molecular cancer therapeutics 7 (12), 3780-3788, 2008 | 93 | 2008 |
| A systematic review of lumbar fusion rates with and without the use of rhBMP-2 F Galimberti, D Lubelski, AT Healy, T Wang, KG Abdullah, AS Nowacki, ... Spine 40 (14), 1132-1139, 2015 | 82 | 2015 |
| Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe F Galimberti, SL Thompson, X Liu, H Li, V Memoli, SR Green, J DiRenzo, ... Clinical Cancer Research 16 (1), 109-120, 2010 | 76 | 2010 |
| Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia Y Guo, AV Dolinko, F Chinyengetere, B Stanton, JM Bomberger, ... Cancer research 70 (23), 9875-9885, 2010 | 65 | 2010 |
| Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models KH Dragnev, T Ma, J Cyrus, F Galimberti, V Memoli, AM Busch, ... Cancer prevention research 4 (6), 818-828, 2011 | 64 | 2011 |
| Anaphase catastrophe is a target for cancer therapy F Galimberti, SL Thompson, S Ravi, DA Compton, E Dmitrovsky Clinical Cancer Research 17 (6), 1218-1222, 2011 | 61 | 2011 |
| Cyclin degradation for cancer therapy and chemoprevention SJ Freemantle, X Liu, Q Feng, F Galimberti, S Blumen, D Sekula, ... Journal of cellular biochemistry 102 (4), 869-877, 2007 | 58 | 2007 |
| Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy‐associated risk factors in a specific tertiary‐care‐centre cohort F Galimberti, Y Li, AP Fernandez British Journal of Dermatology 174 (1), 158-164, 2016 | 55 | 2016 |
| Dermatology consultations significantly contribute quality to care of hospitalized patients: a prospective study of dermatology inpatient consults at a tertiary care center F Galimberti, L Guren, AP Fernandez, A Sood International Journal of Dermatology 55 (10), e547-e551, 2016 | 54 | 2016 |
| Skin findings associated with nutritional deficiencies F Galimberti, NA Mesinkovska Cleve Clin J Med 83 (10), 731-739, 2016 | 50 | 2016 |
| The hedgehog processing pathway is required for NSCLC growth and survival J Rodriguez-Blanco, NS Schilling, R Tokhunts, C Giambelli, J Long, ... Oncogene 32 (18), 2335-2345, 2013 | 47 | 2013 |
| CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110 S Hu, AV Danilov, K Godek, B Orr, LJ Tafe, J Rodriguez-Canales, ... Cancer research 75 (10), 2029-2038, 2015 | 44 | 2015 |
| Evidence for the ubiquitin protease UBP43 as an antineoplastic target Y Guo, F Chinyengetere, AV Dolinko, A Lopez-Aguiar, Y Lu, F Galimberti, ... Molecular cancer therapeutics 11 (9), 1968-1977, 2012 | 44 | 2012 |
| Comparison of the effect of propofol and sevoflurane anaesthesia on acute and chronic postoperative pain after hysterectomy M Ogurlu, S Sari, M Küçük, M Bakiş, B Uğur, YE Eshraghi, F Galimberti, ... Anaesthesia and intensive care 42 (3), 365-370, 2014 | 37 | 2014 |
| Increased, but functionally impaired, CD14+ HLA-DR–/low myeloid-derived suppressor cells in psoriasis: a mechanism of dysregulated T cells DC Soler, AB Young, L Fiessinger, F Galimberti, S Debanne, S Groft, ... Journal of Investigative Dermatology 136 (4), 798-808, 2016 | 30 | 2016 |
| Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer T Ma, F Galimberti, CP Erkmen, V Memoli, F Chinyengetere, L Sempere, ... Molecular cancer therapeutics 12 (8), 1545-1555, 2013 | 28 | 2013 |
| Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis F Galimberti, L Kooistra, Y Li, S Chatterjee, AP Fernandez Clinical and experimental dermatology 43 (8), 906-912, 2018 | 26 | 2018 |
| Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis F Galimberti, Y Li, AP Fernandez Journal of the American Academy of Dermatology 73 (1), 174-176, 2015 | 23 | 2015 |
| Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations F Galimberti, AM Busch, F Chinyengetere, T Ma, D Sekula, VA Memoli, ... International journal of oncology 41 (5), 1751-1761, 2012 | 22 | 2012 |
